Equity Research Pharmaceutical Preparations

Should You Buy Oramed Pharmaceuticals Inc. Stock in 2026?

By CirclFi Research Team · · 10/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Oramed Pharmaceuticals Inc. (ORMP) occupies a solid middle-ground position with a Quality of Company score of 7.0/10. At the current market price of $4.02, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 4 of 10 CirclFi valuation models project upside for Oramed Pharmaceuticals Inc. (ORMP) at $4.02 — the model consensus leans bearish, with a Quality Score of 7.0/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 6 of 10 models suggest overvaluation — majority bearish
  • Quality Score: 7.0/10 — Strong — above-average quality
  • Value Trap Risk: 17/100 — Minimal — healthy fundamentals
  • Fair Value Range: $0.20 – $14.90 (7169% spread)

Bullish Models

4 / 10

Bearish Models

6 / 10

Quality Score

7.0 /10

Strong — above-average quality

Value Trap Risk

17 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

10 /13
Active Models

Avg. confidence: 30%

Investment Thesis

The Bull Case

Target: $14.90 (+270.7% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Oramed Pharmaceuticals Inc.'s rating of 7.0/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably.
  • According to the CirclFi Deep Alpha Valuation Engine, 4 of 10 models identify upside from $4.02 to a composite fair value of $5.38, indicating the market hasn't fully priced in Oramed Pharmaceuticals Inc.'s earnings power.
  • According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $14.90 (+270.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
  • Industry tailwind: regulatory pathway clarity could provide meaningful support for Oramed Pharmaceuticals Inc.'s revenue and margin trajectory in the Pharmaceutical Preparations space.

The Bear Case

Target: $0.20 (-94.9%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.20 (-94.9%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +365.6% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: clinical trial failure represents a meaningful risk for Oramed Pharmaceuticals Inc. and its Pharmaceutical Preparations peers.

Peer Benchmarking

AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0
SIGA SIGA Technologies In
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

7169%

Fair Value Range

$0.20 – $14.90

A 7169% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

RCMH-DCF

$14.90 (+270.7%)

Most Bearish

Bayesian DCF

$0.20 (-94.9%)

Key Risk Factors

Model Disagreement

7169% spread signals high variance in projections.

Bearish Consensus

6/10 models suggest overvaluation.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ORMP Data Page →

The Bottom Line

Caution dominates our read on Oramed Pharmaceuticals Inc. at $4.02. 6 of 10 models see limited upside or outright downside, with the composite fair value at $5.38 (+33.8%). Quality at 7.0/10 provides some fundamental cushion. Current holders should re-evaluate their thesis; new buyers should demand a wider margin of safety.

These are quantitative model outputs, not investment recommendations. Oramed Pharmaceuticals Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy ORMP stock right now?

Based on CirclFi's multi-model analysis, 4 of 10 models see upside for ORMP at $4.02. The models are divided, which means the investment case depends heavily on your assumptions about Oramed Pharmaceuticals Inc.'s future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Oramed Pharmaceuticals Inc.?

Key risks include: wide model disagreement (7169% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does ORMP compare to its competitors?

Among Pharmaceutical Preparations peers, ORMP holds a Quality Score of 7.0/10. Comparable companies include AZN (QOC 10.0), CPRX (QOC 10.0), HRMY (QOC 10.0). The relative ranking helps investors identify whether ORMP offers better fundamental quality than alternatives in the same sector.

Is ORMP a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ORMP's Quality Score of 7.0/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy ORMP at?

CirclFi does not provide target buy prices or price alerts. However, our 10 active models produce fair value estimates ranging from $0.20 to $14.90. At $4.02, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ORMP.

View ORMP Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →